1 Vote

It's an inverse translation I was asked to do about a clinical trial study on drugs. Of course this is scientific writing, it involves terms and other issues. I'd be glad, though, if someone can help me with grammatic/syntactic errors or odd things. Thanks in advance!


Begins here

TITLE “A prospective single-blind, randomized, crossover, replicated, comparative study to establish bioequivalence of medroxyprogesterone 10 mg tablets on healthy subjects: XYZ Pharmaceuticals' Medroxi vs SCHMIEDEL Ltd's Provierot ®”


GLOSSARY AND LIST OF ABBREVIATIONS


A Absorption


AUC Area Under the Concentration Time Curve


AUC0͢ t Area Under the Concentration-Time Curve from Time Zero to Time of Last Sample Intake


AUC0͢ ∞ Area Under the Concentration-Time Curve from Time Zero to Infinity


CBC Complete Blood Count


REFERENCE PRODUCT: Schmiedel Ltd's Provierof ® TEST FORMULATION: XYZ Pharmaceuticals' (Mexico) Medroxi


1. AIMS To determine bioavailability of two medroxyprogesterone pharmaceutic specialties, one of them the reference product: (Drug A: Provierof ®) while the other is the test formulation: (Drug B: Medroxi), on healthy male subjects, in a 40 mg dose (4 tablets) taken orally, under fasting conditions of each examined products to establish its bioequivalence; all of this in order to register them as generics drugs through the trials required by the Official Mexican Standards and not through a demonstration of pharmacokinetic differences within genre populations.


1.1.1. Adverse effects Adverse effects related to use of medroxyprogesterone acetate are: pulmonary embolism, thrombophlebitis, increased platelets aggregate formation, nervousness, drowsiness, fatigue, alopecia, acne, hirsutism, depression, dizzyness, increased bleeding time, cephalalgia, abnormal uterine bleeding, amenorrhea, nausea, galactorrhea, overweight, increasing risk of breast cancer, increasing risk of bone fracture, and variable expression of delayed hypersensitivity (Goodman & Gilman 10th ed. and PDR 61). These drugs are classified under Category X —by FDA's Pregnancy Drug Classifications— due to an increased risk of fetal abnormalities (hypospadias, clitoris enlargement, and labial fusion). The margin of safety (MOS) is high (PDR 61).


1.2. Study's premature end • This study can be interrupted temporarily or discontinued permanently by Sponsor's, Chief Researcher's or Comisión de Ética e Investigación choice according to Mexican Secretariat of Health’s guidelines.


Abstract


TITLE OF STUDY A prospective single-blind, randomized, crossover, replicated, comparative study to establish bioequivalence of medroxyprogesterone 10 mg tablets on healthy subjects: XYZ's Medroxi vs SCHMIEDEL's Provierof ®


RESEARCH OBJECTIVES To compare bioavailability of two medroxyprogesterone commercial products (Provera® vs Medroxiprogesterone) and to establish their bioequivalence.


STUDY DESIGN An experimental, longitudinal, single-blind, comparative, randomized, crossover, ABBA and BAAB design.


POPULATION Thirty-six healthy male subjects and two surplus cases.


PACKAGING 10 mg tablets


DOSE Four tablets taken orally, after a period of 10 hour fasting.


PRETREATMENT Not required.


WASH-OUT TIME Seven days.


REQUIRED LABORATORY STUDIES Full biometrics, complete blood count (CBC, 4 profiles), liver function tests, HIV test, hepatitis B & C tests, VDRL blood test, urine drug test and also, in the case of women, a pregnancy test.


REFERENCE PRODUCT Schmiedel Ltd's Provierof ®


TEST FORMULATION XYZ Pharmaceuticals' (Mexico) Medroxi


ASSESSMENT PARAMETERS A 36 hour follow up in order to get sixteen blood samples, to determinate medroxiprogesterone within plasma and to calculate AUC0͢ t, AUC0͢ ∞and Cmax.


SAMPLING INTERVALS 0.00 (Pre-treatment, Control), 0.33, 0.66, 1.00, 1.33, 1.66, 2.00, 2.33, 2.66, 3.00, 3.50, 4.00, 6.00, 12.00, 24.00 and 36.00 hours after the treatment.

Ends here

  • Posted Mar 30, 2012
  • | 864 views
  • | link
  • | flag
  • Hi and welcome to the forum!. I just made a few suggestions in 1.1.1. dizziness, increased and increased. Double check the scientific terms, but I think they are O K. - sanlee Mar 30, 2012 flag
  • Thanks a lot, sanlee! - mcgg Mar 30, 2012 flag
  • You're welcome, mcgg - sanlee Mar 30, 2012 flag

1 Answer

1 Vote

TITLE “A prospective single-blind, randomized, crossover, replicated, comparative study to establish bioequivalence of medroxyprogesterone 10 mg tablets on healthy subjects: XYZ Pharmaceuticals' Medroxi vs SCHMIEDEL Ltd's Provierot ®”

GLOSSARY AND LIST OF ABBREVIATIONS

A Absorption

AUC Area Under the Concentration Time Curve

AUC0͢ t Area Under the Concentration-Time Curve from Time Zero to Time of Last Sample Intake

AUC0͢ ∞ Area Under the Concentration-Time Curve from Time Zero to Infinity

CBC Complete Blood Count

REFERENCE PRODUCT: Schmiedel Ltd's Provierof ® TEST FORMULATION: XYZ Pharmaceuticals' (Mexico) Medroxi

  1. AIMS To determine bioavailability of two medroxyprogesterone pharmaceutic specialties, one of them the reference product: (Drug A: Provierof ®) while the other is the test formulation: (Drug B: Medroxi), on healthy male subjects, in a 40 mg dose (4 tablets) taken orally, under fasting conditions of each examined products to establish its bioequivalence; all of this in order to register them as generics drugs through the trials required by the Official Mexican Standards and not through a demonstration of pharmacokinetic differences within genre populations.

1.1.1. Adverse effects Adverse effects related to use of medroxyprogesterone acetate are: pulmonary embolism, thrombophlebitis, increased platelets aggregate formation, nervousness, drowsiness, fatigue, alopecia, acne, hirsutism, depression, dizziness, increased bleeding time, cephalalgia, abnormal uterine bleeding, amenorrhea, nausea, galactorrhea, overweight, increased risk of breast cancer, increased risk of bone fracture, and variable expression of delayed hypersensitivity (Goodman & Gilman 10th ed. and PDR 61). These drugs are classified under Category X —by FDA's Pregnancy Drug Classifications— due to an increased risk of fetal abnormalities (hypospadias, clitoris enlargement, and labial fusion). The margin of safety (MOS) is high (PDR 61).

1.2. Study's premature end • This study can be interrupted temporarily or discontinued permanently by Sponsor's, Chief Researcher's or Comisión de Ética e Investigación choice according to Mexican Secretariat of Health’s guidelines.

Abstract

TITLE OF STUDY A prospective single-blind, randomized, crossover, replicated, comparative study to establish bioequivalence of medroxyprogesterone 10 mg tablets on healthy subjects: XYZ's Medroxi vs SCHMIEDEL's Provierof ®

RESEARCH OBJECTIVES To compare bioavailability of two medroxyprogesterone commercial products (Provera® vs Medroxiprogesterone) and to establish their bioequivalence.

STUDY DESIGN An experimental, longitudinal, single-blind, comparative, randomized, crossover, ABBA and BAAB design.

POPULATION Thirty-six healthy male subjects and two surplus cases.

PACKAGING 10 mg tablets

DOSE Four tablets taken orally, after a period of 10 hour fasting.

PRETREATMENT Not required.

WASH-OUT TIME Seven days.

REQUIRED LABORATORY STUDIES Full biometrics, complete blood count (CBC, 4 profiles), liver function tests, HIV test, hepatitis B & C tests, VDRL blood test, urine drug test and also, in the case of women, a pregnancy test.

REFERENCE PRODUCT Schmiedel Ltd's Provierof ®

TEST FORMULATION XYZ Pharmaceuticals' (Mexico) Medroxi

ASSESSMENT PARAMETERS A 36 hour follow up in order to get sixteen blood samples, to determinate medroxiprogesterone within plasma and to calculate AUC0͢ t, AUC0͢ ∞and Cmax.

SAMPLING INTERVALS 0.00 (Pre-treatment, Control), 0.33, 0.66, 1.00, 1.33, 1.66, 2.00, 2.33, 2.66, 3.00, 3.50, 4.00, 6.00, 12.00, 24.00 and 36.00 hours after the treatment.

Ends here
Answer this Question
Download our free app
Connect with SpanishDict
Comentarios